Failed 2026

    Nido Biosciences

    Even well-capitalized biotechs backed by reputable venture studios can be forced to shut down entirely when a single Phase 2 trial in a rare disease indication underperforms.

    TL;DR — Failure Post-Mortem

    Nido Biosciences was a Biotechnology startup founded in 2020 in USA. It raised $109 million before collapsing in 2026 — 6 years of runway burned. IdeaProof's AI Failure Score: 7/100, driven by drug failed phase ii clinical trial. The shutdown affected employees, investors, and the broader Biotechnology ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.

    Why did Nido Biosciences fail?

    Nido Biosciences failed in 2026 after 6 years of operation, losing $109 million in raised capital. The root cause was drug failed phase ii clinical trial. Key lesson: Even well-capitalized biotechs backed by reputable venture studios can be forced to shut down entirely when a single Phase 2 trial in a rare disease indication underperforms.

    Verifiable facts
    Sourced
    Founded → Closed

    2020 → 2026

    Funding Raised

    $109 million

    Industry

    Biotechnology

    Country

    USA

    IdeaProof AI Failure Score

    7/100
    Market Fit Risk
    Burn Rate Risk
    Founder Risk

    What Happened: The Timeline

    •

    2020

    Nido Biosciences founded

    •

    2023

    Emerges from stealth with $109 million

    •

    2025-12

    CEO announces Phase 2 underperformed; company will wind down

    •

    2026-01

    Full shutdown expected

    Root Causes

    Lead neurological disease candidate failed to move the needle in a Phase 2 rare disease trial
    Underwhelming efficacy data eliminated the near-term path to further funding or partnership
    Difficulty of drug development in rare, complex neurological disease indications
    Limited runway after $109 million raised without a de-risked follow-on asset

    Nido Biosciences was a Watertown, Massachusetts biotech founded in 2020 by 5AM Ventures' 4:59 Initiative to treat debilitating neurological diseases. The company emerged from stealth in 2023 with $109 million. Over ~5 years, Nido advanced its lead candidate into Phase 2 for a rare neurological disease. In late December 2025, CEO Jeremy P. Springhorn announced the Phase 2 study came in below expectations, failing to demonstrate clinically meaningful benefit. The company will wind down, with full shutdown expected in early 2026. The closure reflects a broader trend of biotech wind-downs in late 2025/early 2026 amid a challenging funding environment.

    Causal Chain

    Derived · heuristic

    This is our reading of the causal chain — separated from the verifiable facts above. Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.

    Root cause

    A combination of demand-side, execution, and capital-market pressures that this record documents without isolating a single dominant driver.

    Contributing factors
    • Lead neurological disease candidate failed to move the needle in a Phase 2 rare disease trial
    • Underwhelming efficacy data eliminated the near-term path to further funding or partnership
    • Difficulty of drug development in rare, complex neurological disease indications
    • Limited runway after $109 million raised without a de-risked follow-on asset
    Terminal event

    2026: cessation of operations after failing to secure additional capital or a strategic buyer.

    Base rates

    External sources

    A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching Nido Biosciences's profile. Sources are third-party; we do not restate them as our own claims.

    ~97%
    industry

    of venture-backed consumer hardware startups do not reach a profitable exit within 10 years — hardware requires atypical capital efficiency to survive.

    PitchBook Emerging Tech Research (2023)
    ~70%
    industry

    of digital-health startups fail to reach breakeven; reimbursement complexity + regulatory approvals extend runway needs beyond typical VC horizons.

    Rock Health State of Digital Health (2023)
    ~90%
    all

    of startups ultimately fail — including ~10% that fail in the first year and the rest across the following decade.

    Startup Genome / CB Insights aggregate (2024)
    ~35%
    all

    of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).

    US Bureau of Labor Statistics — BED (2024)
    ~35%
    stage

    of Series A rounds ever graduate to Series B; the rest run out of runway or pivot without a follow-on.

    CB Insights Venture Capital Funnel (2023)

    Key Lessons Learned

    1. Lead neurological disease candidate failed to move the needle in a Phase 2 rare disease trial

    Lead neurological disease candidate failed to move the needle in a Phase 2 rare disease trial — a recurring pattern across biotechnology failures. Validate this risk before you scale.

    2. Underwhelming efficacy data eliminated the near-term path to further funding or partnership

    Underwhelming efficacy data eliminated the near-term path to further funding or partnership — a recurring pattern across biotechnology failures. Validate this risk before you scale.

    3. Difficulty of drug development in rare, complex neurological disease indications

    Difficulty of drug development in rare, complex neurological disease indications — a recurring pattern across biotechnology failures. Validate this risk before you scale.

    Frequently Asked Questions

    Sources & Confidence

    Every data point is tagged with its source type and our confidence in it. How we grade sources.

    Additional references
    Neuro biotech Nido closes after 5 years

    Could This Failure Have Been Prevented?

    IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Nido Biosciences.

    Related Failures

    Sichuan Kelun-Biotech

    $400M · 2024

    Capital inefficiency, weak pipeline, market saturation

    Base Therapeutics

    $34.5M · 2025

    Product/tech failure, capital inefficiency

    IO Biotech

    $170M · 2026

    Filed for Chapter 7 bankruptcy

    Lipella Pharmaceuticals

    Under $20m · 2026

    Bankruptcy, inability to develop drug

    Spotted a factual error?

    Approved corrections are published in the public changelog with attribution.

    After Nido Biosciences: hubs, comparisons and deep dives

    Compare the validation, funding and go-to-market choices that separate survivors from failures like Nido Biosciences.